Protein therapeutics: a summary and pharmacological classification View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-01

AUTHORS

Benjamin Leader, Quentin J. Baca, David E. Golan

ABSTRACT

The number and frequency of use of protein therapeutics has increased dramatically since the introduction of the first recombinant protein therapeutic — human insulin — 25 years ago. Golan and colleagues overview some of the key characteristics of protein therapeutics, summarize the more than 130 protein therapeutics used currently and suggest a new classification of these proteins based on their pharmacological action. More... »

PAGES

21-39

References to SciGraph publications

  • 2001-02-15. Initial sequencing and analysis of the human genome in NATURE
  • 2004-03. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes in NATURE REVIEWS DRUG DISCOVERY
  • 1986-12. Testing with growth hormone-releasing factor (GRF(1–29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency in EUROPEAN JOURNAL OF PEDIATRICS
  • 2003-06. Abciximab in DRUGS
  • 1983-09. Cleansing properties of stabilized trypsin and streptokinase-streptodornase in necrotic leg ulcers in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2002-12. Protein engineering 20 years on in NATURE REVIEWS MOLECULAR CELL BIOLOGY
  • 2007-02. GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1992-10. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin in NATURE
  • 1993-09. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 in NATURE
  • 1998-05. Intercellular delivery of functional p53 by the herpesvirus protein VP22 in NATURE BIOTECHNOLOGY
  • 2002-03. Ethics, Policy, and Rare Genetic Disorders: The Case of Gaucher Disease in Israel in THEORETICAL MEDICINE AND BIOETHICS
  • 1993-03. Process Economics of Animal Cell and Bacterial Fermentations: A Case Study Analysis of Tissue Plasminogen Activator in BIO/TECHNOLOGY
  • 2004-05-01. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer in NATURE REVIEWS DRUG DISCOVERY
  • 2005-05. Cetuximab in NATURE REVIEWS DRUG DISCOVERY
  • 2005-04. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins in CLINICAL PHARMACOKINETICS
  • 2006-02. Galsulfase in NATURE REVIEWS DRUG DISCOVERY
  • 2001-04-03. Development and characterization of novel erythropoiesis stimulating protein (NESP) in BRITISH JOURNAL OF CANCER
  • 1997-11. Increased sensitivity of HIV-1 antibody detection in NATURE MEDICINE
  • 1992-07. Alglucerase in DRUGS
  • 2002-06. Bioequivalence and the immunogenicity of biopharmaceuticals in NATURE REVIEWS DRUG DISCOVERY
  • 2005-04. Protein drug stability: a formulation challenge in NATURE REVIEWS DRUG DISCOVERY
  • 2005-05-27. Effect of hyaluronidase on ocular motility and eyelid function in sub-Tenon's anaesthesia: randomised controlled trial in EYE
  • 2004-05. Octagam® 5%, an Intravenous IgG Product, Is Efficacious and Well Tolerated in Subjects with Primary Immunodeficiency Diseases in JOURNAL OF CLINICAL IMMUNOLOGY
  • 2007-05. Development trends for monoclonal antibody cancer therapeutics in NATURE REVIEWS DRUG DISCOVERY
  • 2003-09. Trends in development and approval times for new therapeutics in the United States in NATURE REVIEWS DRUG DISCOVERY
  • 2004-01. Oxaliplatin in NATURE REVIEWS DRUG DISCOVERY
  • 1998-02. Improving protein therapeutics with sustained-release formulations in NATURE BIOTECHNOLOGY
  • Journal

    TITLE

    Nature Reviews Drug Discovery

    ISSUE

    1

    VOLUME

    7

    Related Patents

  • Inhibition Of Protein Degradation For Improved Production
  • Modified Polynucleotides For Treating Galactosylceramidase Protein Deficiency
  • Modified Polynucleotides For The Production Of Secreted Proteins
  • Delivery System For Functional Nucleases
  • General And Direct Method Of Preparing Oligonucleotide-Functionalized Metal-Organic Framework Nanoparticles
  • Methods For Manufacturing Recombinant Protein Comprising A Disulfide Bond
  • A Method For Producing Biologic Product Variants
  • Modified Polynucleotides For The Production Of Biologics And Proteins Associated With Human Disease
  • Modified Polynucleotides Encoding Granulysin
  • Distributed Perfusion Bioreactor System For Continuous Culture Of Biological Cells
  • Engineered Nucleic Acids Encoding A Modified Erythropoietin And Their Expression
  • Nanoparticles Having Poly(Ester Amide) Polymer Cores As Drug Delivery Vehicles
  • Unstructured Non-Repetitive Polypeptides Having Lcst Behavior
  • Methods Of Analyzing Pluralities Of Cells And Detecting Protein Sequence Variants In Biological Product Manufacturing
  • Polymer Conjugates Having Reduced Antigenicity And Methods Of Using The Same
  • A Composition For Controlled Release Of A Biomolecule, Method Of Preparation And Uses Thereof
  • Methods Of Assaying Tropolone
  • Methods Of Cell Selection And Modifying Cell Metabolism
  • Modulation Of Lipid Metabolism For Protein Production
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Synthetic 5' Utr Sequences, And High-Throughput Engineering And Screening Thereof
  • Treating Cardiovascular Or Renal Diseases
  • Modified Polynucleotides For The Production Of Nuclear Proteins
  • Polymers For Delivery Of Therapeutic Proteins
  • Modified Polynucleotides For Treating Protein Deficiency
  • Treating Cardiovascular Or Renal Diseases
  • Methods For Improving Production Of Biological Products By Reducing The Level Of Endogenous Protein
  • Method For Stabilizing Proteins
  • Peptide Derivatives And Use Thereof As Carriers For Molecules In The Form Of Conjugates
  • Method For Stabilizing Proteins
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Modified Polynucleotides Encoding Cited4
  • Modulation Of Lipid Metabolism For Protein Production
  • Modified Polynucleotides Encoding Apoptosis Inducing Factor 1
  • Modified Polynucleotides Encoding Septin-4
  • Delivery And Formulation Of Engineered Nucleic Acids
  • Implantable Bio-Resorbable Polymer Charged With Fragile Macromolecules
  • Delivery System For Functional Nucleases
  • Enzyme Responsive Nanocapsules For Protein Delivery
  • Triblock Polypeptide-Based Nanoparticles For The Delivery Of Hydrophilic Drugs
  • Proteomic Analysis Of Host Cell Proteins
  • Formulation And Delivery Of Plga Microspheres
  • Modified Polynucleotides Encoding Basic Helix-Loop-Helix Family Member E41
  • Compositions And Methods For The Detection Of Host Cell Proteins
  • Delivery And Formulation Of Engineered Nucleic Acids
  • Compositions And Methods For The Detection Of Host Cell Proteins
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Treating Cardiovascular Or Renal Diseases
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Portable Fluidic Platform For Rapid Cell-Free Production Of Protein Biologics
  • Compositions And Methods Of Altering Cholesterol Levels
  • Polynucleotides Encoding Immune Modulating Polypeptides
  • Modified Polynucleotides For The Production Of Proteins Associated With Human Disease
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Modified Polynucleotides Encoding Copper Metabolism (Murr1) Domain Containing 1
  • Modified Polynucleotides For The Production Of Proteins
  • Portable Fluidic Platform For Rapid Cell-Free Production Of Protein Biologics
  • Modified Polynucleotides For The Production Of Secreted Proteins
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Methods For Cell-Free Protein Synthesis
  • Modified Polynucleotides For The Production Of Cosmetic Proteins And Peptides
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Modified Polynucleotides Encoding Hepatitis A Virus Cellular Receptor 2
  • Modified Polynucleotides Encoding Siah E3 Ubiquitin Protein Ligase 1
  • Polymer Conjugates Having Reduced Antigenicity And Methods Of Using The Same
  • Natriuretic Polypeptides
  • Modified Polynucleotides For The Production Of G-Csf
  • Dlin-Kc2-Dma Lipid Nanoparticle Delivery Of Modified Polynucleotides
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Tissue Catalyzed Growth Of Polymer As Epithelial Linings For Therapy
  • Methods Of Cell Selection And Modifying Cell Metabolism
  • Polymers For Delivery Of Factor Viii And/Or Factor Ix
  • Peptide Derivatives And Use Thereof As Carriers For Molecules In The Form Of Conjugates
  • Terminally Modified Rna
  • Polynucleotides Encoding Low Density Lipoprotein Receptor
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Fibronectin Type Iii Domain-Based Fusion Proteins
  • In Vivo Production Of Proteins
  • Delivery Of Negatively Charged Proteins Using Cationic Lipids
  • Modified Polynucleotides For The Production Of Oncology-Related Proteins And Peptides
  • Natriuretic Polypeptides
  • Natriuretic Polypeptides
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Releasable Glp-1 Conjugates
  • Modified Polynucleotides For The Production Of Biologics And Proteins Associated With Human Disease
  • Modified Polynucleotides Encoding Aryl Hydrocarbon Receptor Nuclear Translocator
  • Formulation And Delivery Of Plga Microspheres
  • Modified Polynucleotides For The Production Of Proteins Associated With Blood And Lymphatic Disorders
  • Method And System For Providing Buffer Solutions
  • Modified Polynucleotides Encoding Aquaporin-5
  • Multiple-Enzyme Nanocomplexes
  • Modified Polynucleotides For The Production Of Cytoplasmic And Cytoskeletal Proteins
  • Universal Self-Regulating Mammalian Cell Line Platform For The Production Of Biologics
  • Natriuretic Polypeptides
  • Modified Polynucleotides For The Production Of Proteins Associated With Blood And Lymphatic Disorders
  • Modified Polynucleotides
  • High Concentration Protein Formulations With Reduced Viscosity
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Modified Polynucleotides For The Production Of Cytoplasmic And Cytoskeletal Proteins
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Method For Producing A Protein Of Interest In A Primate
  • Inhibitors Of Tnf Superfamily Costimulatory Interactions And Methods For Uses Of The Same
  • Split Dose Administration
  • Modified Polynucleotides For The Production Of Proteins
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nrd2399

    DOI

    http://dx.doi.org/10.1038/nrd2399

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1051687311

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/18097458


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cystic Fibrosis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cystic Fibrosis Transmembrane Conductance Regulator", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Darbepoetin alfa", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Diabetes Mellitus", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Erythropoietin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Insulin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Deficiency", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recombinant Proteins", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Benjamin Leader is at the Department of Emergency Medicine, Brown Medical School, 593 Eddy Street, Providence, Rhode Island 02093, USA.", 
              "id": "http://www.grid.ac/institutes/grid.40263.33", 
              "name": [
                "Benjamin Leader is at the Department of Emergency Medicine, Brown Medical School, 593 Eddy Street, Providence, Rhode Island 02093, USA."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Leader", 
            "givenName": "Benjamin", 
            "id": "sg:person.012404661625.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012404661625.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Quentin J. Baca and David E. Golan are at the Department of Biological Chemistry and Molecular Pharmacology, and Hematology Division, 250 Longwood Avenue, Harvard Medical School, Boston, Massachusetts 02115, USA, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115.", 
              "id": "http://www.grid.ac/institutes/grid.38142.3c", 
              "name": [
                "Quentin J. Baca and David E. Golan are at the Department of Biological Chemistry and Molecular Pharmacology, and Hematology Division, 250 Longwood Avenue, Harvard Medical School, Boston, Massachusetts 02115, USA, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Baca", 
            "givenName": "Quentin J.", 
            "id": "sg:person.0671026344.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671026344.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Quentin J. Baca and David E. Golan are at the Department of Biological Chemistry and Molecular Pharmacology, and Hematology Division, 250 Longwood Avenue, Harvard Medical School, Boston, Massachusetts 02115, USA, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115.", 
              "id": "http://www.grid.ac/institutes/grid.38142.3c", 
              "name": [
                "Quentin J. Baca and David E. Golan are at the Department of Biological Chemistry and Molecular Pharmacology, and Hematology Division, 250 Longwood Avenue, Harvard Medical School, Boston, Massachusetts 02115, USA, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Golan", 
            "givenName": "David E.", 
            "id": "sg:person.01144174070.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144174070.48"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nbt0598-440", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017023698", 
              "https://doi.org/10.1038/nbt0598-440"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1197-1258", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032140480", 
              "https://doi.org/10.1038/nm1197-1258"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1178", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016939883", 
              "https://doi.org/10.1038/nrd1178"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1381", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006489607", 
              "https://doi.org/10.1038/nrd1381"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-200363110-00014", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009305869", 
              "https://doi.org/10.2165/00003495-200363110-00014"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrm975", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045034030", 
              "https://doi.org/10.1038/nrm975"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/b:joci.0000025453.23817.3f", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035719758", 
              "https://doi.org/10.1023/b:joci.0000025453.23817.3f"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.eye.6701931", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021574878", 
              "https://doi.org/10.1038/sj.eye.6701931"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1695", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019770135", 
              "https://doi.org/10.1038/nrd1695"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd2241", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025602916", 
              "https://doi.org/10.1038/nrd2241"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1020324332620", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045508228", 
              "https://doi.org/10.1023/a:1020324332620"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.clpt.6100055", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016642853", 
              "https://doi.org/10.1038/sj.clpt.6100055"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-200544040-00001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008516954", 
              "https://doi.org/10.2165/00003088-200544040-00001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1287", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016859592", 
              "https://doi.org/10.1038/nrd1287"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/359832a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005284215", 
              "https://doi.org/10.1038/359832a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-199244010-00007", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012144121", 
              "https://doi.org/10.2165/00003495-199244010-00007"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35057062", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042854081", 
              "https://doi.org/10.1038/35057062"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1962", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036526375", 
              "https://doi.org/10.1038/nrd1962"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1331", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006208183", 
              "https://doi.org/10.1038/nrd1331"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1054/bjoc.2001.1746", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019263999", 
              "https://doi.org/10.1054/bjoc.2001.1746"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0393-349", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007397833", 
              "https://doi.org/10.1038/nbt0393-349"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00542211", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004240596", 
              "https://doi.org/10.1007/bf00542211"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1728", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047748539", 
              "https://doi.org/10.1038/nrd1728"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd818", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027741970", 
              "https://doi.org/10.1038/nrd818"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/365160a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009090482", 
              "https://doi.org/10.1038/365160a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02429048", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010985339", 
              "https://doi.org/10.1007/bf02429048"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0298-153", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019139570", 
              "https://doi.org/10.1038/nbt0298-153"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2008-01", 
        "datePublishedReg": "2008-01-01", 
        "description": "The number and frequency of use of protein therapeutics has increased dramatically since the introduction of the first recombinant protein therapeutic \u2014 human insulin \u2014 25 years ago. Golan and colleagues overview some of the key characteristics of protein therapeutics, summarize the more than 130 protein therapeutics used currently and suggest a new classification of these proteins based on their pharmacological action.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nrd2399", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2683815", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2635682", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2699384", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1327423", 
            "issn": [
              "1474-1776", 
              "1474-1784"
            ], 
            "name": "Nature Reviews Drug Discovery", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "7"
          }
        ], 
        "keywords": [
          "protein therapeutics", 
          "pharmacological actions", 
          "pharmacological classification", 
          "therapeutics", 
          "frequency of use", 
          "protein", 
          "new classification", 
          "years", 
          "Golan", 
          "summary", 
          "classification", 
          "action", 
          "use", 
          "number", 
          "key characteristics", 
          "frequency", 
          "colleagues", 
          "characteristics", 
          "introduction"
        ], 
        "name": "Protein therapeutics: a summary and pharmacological classification", 
        "pagination": "21-39", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1051687311"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nrd2399"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "18097458"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nrd2399", 
          "https://app.dimensions.ai/details/publication/pub.1051687311"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T16:56", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_471.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nrd2399"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrd2399'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrd2399'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrd2399'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrd2399'


     

    This table displays all metadata directly associated to this object as RDF triples.

    251 TRIPLES      21 PREDICATES      82 URIs      47 LITERALS      17 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nrd2399 schema:about N0146f47c9d2042ed97689e07a961581d
    2 N01fddfcd5f0042389155820670ac4e3e
    3 N03d91ffdb7a743e897a5d78538729dcd
    4 N1bff45a4c44d467b9cdc46fbca098fd6
    5 N6fa097917804412f8c3dc3fbdf4d6e0b
    6 Na3c2fa862aa749a888bd9db61c603773
    7 Na72480d124e64330b6676ad1149d23d9
    8 Nad7a5beaa4c54795925176ef76e01865
    9 Nb0e96bd6cddf432c8f02c37b5645480c
    10 Ned65dc485a7d4c868ea0cb8ad369a981
    11 anzsrc-for:06
    12 anzsrc-for:0601
    13 schema:author N291f78ae4e3841a4aded60a3771fff8c
    14 schema:citation sg:pub.10.1007/bf00542211
    15 sg:pub.10.1007/bf02429048
    16 sg:pub.10.1023/a:1020324332620
    17 sg:pub.10.1023/b:joci.0000025453.23817.3f
    18 sg:pub.10.1038/35057062
    19 sg:pub.10.1038/359832a0
    20 sg:pub.10.1038/365160a0
    21 sg:pub.10.1038/nbt0298-153
    22 sg:pub.10.1038/nbt0393-349
    23 sg:pub.10.1038/nbt0598-440
    24 sg:pub.10.1038/nm1197-1258
    25 sg:pub.10.1038/nrd1178
    26 sg:pub.10.1038/nrd1287
    27 sg:pub.10.1038/nrd1331
    28 sg:pub.10.1038/nrd1381
    29 sg:pub.10.1038/nrd1695
    30 sg:pub.10.1038/nrd1728
    31 sg:pub.10.1038/nrd1962
    32 sg:pub.10.1038/nrd2241
    33 sg:pub.10.1038/nrd818
    34 sg:pub.10.1038/nrm975
    35 sg:pub.10.1038/sj.clpt.6100055
    36 sg:pub.10.1038/sj.eye.6701931
    37 sg:pub.10.1054/bjoc.2001.1746
    38 sg:pub.10.2165/00003088-200544040-00001
    39 sg:pub.10.2165/00003495-199244010-00007
    40 sg:pub.10.2165/00003495-200363110-00014
    41 schema:datePublished 2008-01
    42 schema:datePublishedReg 2008-01-01
    43 schema:description The number and frequency of use of protein therapeutics has increased dramatically since the introduction of the first recombinant protein therapeutic — human insulin — 25 years ago. Golan and colleagues overview some of the key characteristics of protein therapeutics, summarize the more than 130 protein therapeutics used currently and suggest a new classification of these proteins based on their pharmacological action.
    44 schema:genre article
    45 schema:isAccessibleForFree false
    46 schema:isPartOf N33e36f637227441db412246abf3c50b2
    47 Nd3a70afb4ecd4708ac0431f0d0c2b742
    48 sg:journal.1327423
    49 schema:keywords Golan
    50 action
    51 characteristics
    52 classification
    53 colleagues
    54 frequency
    55 frequency of use
    56 introduction
    57 key characteristics
    58 new classification
    59 number
    60 pharmacological actions
    61 pharmacological classification
    62 protein
    63 protein therapeutics
    64 summary
    65 therapeutics
    66 use
    67 years
    68 schema:name Protein therapeutics: a summary and pharmacological classification
    69 schema:pagination 21-39
    70 schema:productId N20ff9de26831421ab7dc5f6afcc1b7c6
    71 N9940b7f151b541d5817a3d4bb6bd6f30
    72 Nd36f8fb7001442b98541ebbf4a28b4a8
    73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051687311
    74 https://doi.org/10.1038/nrd2399
    75 schema:sdDatePublished 2022-08-04T16:56
    76 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    77 schema:sdPublisher N2713d9f4fe88485ba01f56fbff4e21a8
    78 schema:url https://doi.org/10.1038/nrd2399
    79 sgo:license sg:explorer/license/
    80 sgo:sdDataset articles
    81 rdf:type schema:ScholarlyArticle
    82 N0146f47c9d2042ed97689e07a961581d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    83 schema:name Protein Deficiency
    84 rdf:type schema:DefinedTerm
    85 N01fddfcd5f0042389155820670ac4e3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    86 schema:name Insulin
    87 rdf:type schema:DefinedTerm
    88 N03d91ffdb7a743e897a5d78538729dcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    89 schema:name Diabetes Mellitus
    90 rdf:type schema:DefinedTerm
    91 N1bff45a4c44d467b9cdc46fbca098fd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    92 schema:name Cystic Fibrosis Transmembrane Conductance Regulator
    93 rdf:type schema:DefinedTerm
    94 N20ff9de26831421ab7dc5f6afcc1b7c6 schema:name dimensions_id
    95 schema:value pub.1051687311
    96 rdf:type schema:PropertyValue
    97 N2713d9f4fe88485ba01f56fbff4e21a8 schema:name Springer Nature - SN SciGraph project
    98 rdf:type schema:Organization
    99 N291f78ae4e3841a4aded60a3771fff8c rdf:first sg:person.012404661625.05
    100 rdf:rest N2f1d33db7304411e966997703e576149
    101 N2f1d33db7304411e966997703e576149 rdf:first sg:person.0671026344.96
    102 rdf:rest N76e99d482afa4924819172db89138ea2
    103 N33e36f637227441db412246abf3c50b2 schema:volumeNumber 7
    104 rdf:type schema:PublicationVolume
    105 N6fa097917804412f8c3dc3fbdf4d6e0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Humans
    107 rdf:type schema:DefinedTerm
    108 N76e99d482afa4924819172db89138ea2 rdf:first sg:person.01144174070.48
    109 rdf:rest rdf:nil
    110 N9940b7f151b541d5817a3d4bb6bd6f30 schema:name doi
    111 schema:value 10.1038/nrd2399
    112 rdf:type schema:PropertyValue
    113 Na3c2fa862aa749a888bd9db61c603773 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Recombinant Proteins
    115 rdf:type schema:DefinedTerm
    116 Na72480d124e64330b6676ad1149d23d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Cystic Fibrosis
    118 rdf:type schema:DefinedTerm
    119 Nad7a5beaa4c54795925176ef76e01865 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Erythropoietin
    121 rdf:type schema:DefinedTerm
    122 Nb0e96bd6cddf432c8f02c37b5645480c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Darbepoetin alfa
    124 rdf:type schema:DefinedTerm
    125 Nd36f8fb7001442b98541ebbf4a28b4a8 schema:name pubmed_id
    126 schema:value 18097458
    127 rdf:type schema:PropertyValue
    128 Nd3a70afb4ecd4708ac0431f0d0c2b742 schema:issueNumber 1
    129 rdf:type schema:PublicationIssue
    130 Ned65dc485a7d4c868ea0cb8ad369a981 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Proteins
    132 rdf:type schema:DefinedTerm
    133 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    134 schema:name Biological Sciences
    135 rdf:type schema:DefinedTerm
    136 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    137 schema:name Biochemistry and Cell Biology
    138 rdf:type schema:DefinedTerm
    139 sg:grant.2635682 http://pending.schema.org/fundedItem sg:pub.10.1038/nrd2399
    140 rdf:type schema:MonetaryGrant
    141 sg:grant.2683815 http://pending.schema.org/fundedItem sg:pub.10.1038/nrd2399
    142 rdf:type schema:MonetaryGrant
    143 sg:grant.2699384 http://pending.schema.org/fundedItem sg:pub.10.1038/nrd2399
    144 rdf:type schema:MonetaryGrant
    145 sg:journal.1327423 schema:issn 1474-1776
    146 1474-1784
    147 schema:name Nature Reviews Drug Discovery
    148 schema:publisher Springer Nature
    149 rdf:type schema:Periodical
    150 sg:person.01144174070.48 schema:affiliation grid-institutes:grid.38142.3c
    151 schema:familyName Golan
    152 schema:givenName David E.
    153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144174070.48
    154 rdf:type schema:Person
    155 sg:person.012404661625.05 schema:affiliation grid-institutes:grid.40263.33
    156 schema:familyName Leader
    157 schema:givenName Benjamin
    158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012404661625.05
    159 rdf:type schema:Person
    160 sg:person.0671026344.96 schema:affiliation grid-institutes:grid.38142.3c
    161 schema:familyName Baca
    162 schema:givenName Quentin J.
    163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671026344.96
    164 rdf:type schema:Person
    165 sg:pub.10.1007/bf00542211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004240596
    166 https://doi.org/10.1007/bf00542211
    167 rdf:type schema:CreativeWork
    168 sg:pub.10.1007/bf02429048 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010985339
    169 https://doi.org/10.1007/bf02429048
    170 rdf:type schema:CreativeWork
    171 sg:pub.10.1023/a:1020324332620 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045508228
    172 https://doi.org/10.1023/a:1020324332620
    173 rdf:type schema:CreativeWork
    174 sg:pub.10.1023/b:joci.0000025453.23817.3f schema:sameAs https://app.dimensions.ai/details/publication/pub.1035719758
    175 https://doi.org/10.1023/b:joci.0000025453.23817.3f
    176 rdf:type schema:CreativeWork
    177 sg:pub.10.1038/35057062 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042854081
    178 https://doi.org/10.1038/35057062
    179 rdf:type schema:CreativeWork
    180 sg:pub.10.1038/359832a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005284215
    181 https://doi.org/10.1038/359832a0
    182 rdf:type schema:CreativeWork
    183 sg:pub.10.1038/365160a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009090482
    184 https://doi.org/10.1038/365160a0
    185 rdf:type schema:CreativeWork
    186 sg:pub.10.1038/nbt0298-153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019139570
    187 https://doi.org/10.1038/nbt0298-153
    188 rdf:type schema:CreativeWork
    189 sg:pub.10.1038/nbt0393-349 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007397833
    190 https://doi.org/10.1038/nbt0393-349
    191 rdf:type schema:CreativeWork
    192 sg:pub.10.1038/nbt0598-440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017023698
    193 https://doi.org/10.1038/nbt0598-440
    194 rdf:type schema:CreativeWork
    195 sg:pub.10.1038/nm1197-1258 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032140480
    196 https://doi.org/10.1038/nm1197-1258
    197 rdf:type schema:CreativeWork
    198 sg:pub.10.1038/nrd1178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016939883
    199 https://doi.org/10.1038/nrd1178
    200 rdf:type schema:CreativeWork
    201 sg:pub.10.1038/nrd1287 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016859592
    202 https://doi.org/10.1038/nrd1287
    203 rdf:type schema:CreativeWork
    204 sg:pub.10.1038/nrd1331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006208183
    205 https://doi.org/10.1038/nrd1331
    206 rdf:type schema:CreativeWork
    207 sg:pub.10.1038/nrd1381 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006489607
    208 https://doi.org/10.1038/nrd1381
    209 rdf:type schema:CreativeWork
    210 sg:pub.10.1038/nrd1695 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019770135
    211 https://doi.org/10.1038/nrd1695
    212 rdf:type schema:CreativeWork
    213 sg:pub.10.1038/nrd1728 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047748539
    214 https://doi.org/10.1038/nrd1728
    215 rdf:type schema:CreativeWork
    216 sg:pub.10.1038/nrd1962 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036526375
    217 https://doi.org/10.1038/nrd1962
    218 rdf:type schema:CreativeWork
    219 sg:pub.10.1038/nrd2241 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025602916
    220 https://doi.org/10.1038/nrd2241
    221 rdf:type schema:CreativeWork
    222 sg:pub.10.1038/nrd818 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027741970
    223 https://doi.org/10.1038/nrd818
    224 rdf:type schema:CreativeWork
    225 sg:pub.10.1038/nrm975 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045034030
    226 https://doi.org/10.1038/nrm975
    227 rdf:type schema:CreativeWork
    228 sg:pub.10.1038/sj.clpt.6100055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016642853
    229 https://doi.org/10.1038/sj.clpt.6100055
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.1038/sj.eye.6701931 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021574878
    232 https://doi.org/10.1038/sj.eye.6701931
    233 rdf:type schema:CreativeWork
    234 sg:pub.10.1054/bjoc.2001.1746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019263999
    235 https://doi.org/10.1054/bjoc.2001.1746
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.2165/00003088-200544040-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008516954
    238 https://doi.org/10.2165/00003088-200544040-00001
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.2165/00003495-199244010-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012144121
    241 https://doi.org/10.2165/00003495-199244010-00007
    242 rdf:type schema:CreativeWork
    243 sg:pub.10.2165/00003495-200363110-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009305869
    244 https://doi.org/10.2165/00003495-200363110-00014
    245 rdf:type schema:CreativeWork
    246 grid-institutes:grid.38142.3c schema:alternateName Quentin J. Baca and David E. Golan are at the Department of Biological Chemistry and Molecular Pharmacology, and Hematology Division, 250 Longwood Avenue, Harvard Medical School, Boston, Massachusetts 02115, USA, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115.
    247 schema:name Quentin J. Baca and David E. Golan are at the Department of Biological Chemistry and Molecular Pharmacology, and Hematology Division, 250 Longwood Avenue, Harvard Medical School, Boston, Massachusetts 02115, USA, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115.
    248 rdf:type schema:Organization
    249 grid-institutes:grid.40263.33 schema:alternateName Benjamin Leader is at the Department of Emergency Medicine, Brown Medical School, 593 Eddy Street, Providence, Rhode Island 02093, USA.
    250 schema:name Benjamin Leader is at the Department of Emergency Medicine, Brown Medical School, 593 Eddy Street, Providence, Rhode Island 02093, USA.
    251 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...